These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Sertindole for the treatment of schizophrenia.
    Author: Azorin JM, Kaladjian A, Fakra E, Adida M.
    Journal: Expert Opin Pharmacother; 2010 Dec; 11(18):3053-64. PubMed ID: 21080854.
    Abstract:
    IMPORTANCE OF THE FIELD: Despite considerable progress in the pharmacological treatment of schizophrenia, unmet needs remain concerning refractory patients, as well as improvement of negative symptoms, cognition, quality of life, adherence and tolerability. Sertindole, a second-generation antipsychotic with high affinity for dopamine D₂, serotonin 5-HT₂(A), 5-HT₂(C), and α₁-adrenergic receptors, is the first phenylindole-derived antipsychotic agent. AREAS COVERED IN THIS REVIEW: Pharmacodynamics, pharmacokinetics, clinical efficacy, safety and cost-effectiveness of sertindole are covered based on a literature review (PubMed) from 1990 to 2010. Pivotal as well as supportive randomized controlled trials are reviewed along with observational and/or naturalistic safety studies. WHAT THE READER WILL GAIN: This review of sertindole will allow the reader to determine the place for sertindole in the schizophrenia treatment landscape. TAKE HOME MESSAGE: Studies conducted so far suggest a beneficial effect of sertindole on positive and negative symptoms as well as on cognition, relapse prevention and quality of life. There is also some evidence for the treatment of refractory patients. Sertindole induces moderate weight gain, with few extrapyramidal symptoms and metabolic changes. More head-to-head comparisons with other second-generation antipsychotics are, however, still needed as well as further clarification on cardiac safety.
    [Abstract] [Full Text] [Related] [New Search]